Journal
BLOOD
Volume 129, Issue 17, Pages 2375-2383Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2016-12-758409
Keywords
-
Categories
Funding
- Sanofi Genzyme
- UK Medical Research Council [MR/K015338/1]
- National Institutes of Health Research, Cambridge Biomedical Research Centre (Metabolic theme)
- Medical Research Council [MR/K015338/1, MR/K025570/1] Funding Source: researchfish
- Sparks Charity [14CAM03] Funding Source: researchfish
- MRC [MR/K015338/1, MR/K025570/1] Funding Source: UKRI
Ask authors/readers for more resources
In the phase 3 Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE), at 1 year, eliglustat was noninferior to imiglucerase enzyme therapy in maintaining stable platelet counts, hemoglobin concentrations, and spleen and liver volumes. After this primary analysis period, patients entered a long-term extension phase in which all received eliglustat. Duration on eliglustat ranged from 2 to 5 years, depending on timing of enrollment (which spanned 2 years), treatment group to which patients were randomized, and whether they lived in the United States when commercial eliglustat became available. Here we report long-term safety and efficacy of eliglustat for 157 patients who received eliglustat in the ENCORE trial; data are available for 46 patients who received eliglustat for 4 years. Mean hemoglobin concentration, platelet count, and spleen and liver volumes remained stable for up to 4 years. Year to year, all 4 measures remained collectively stable (composite end point relative to baseline values) in >= 85% of patients as well as individually in >= 92%. Mean bone mineral density z scores (lumbar spine and femur) remained stable and were maintained in the healthy reference range throughout. Eliglustat was well tolerated over 4 years; 4 (2.5%) patients withdrew because of adverse events that were considered related to the study drug. No new or long-term safety concerns were identified. Clinical stability assessed by composite and individual measures was maintained in adults with Gaucher disease type 1 treated with eliglustat who remained in the ENCORE trial for up to 4 years.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available